Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 14 points (0.1%) at 16,515 as of Thursday, April 24, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,645 issues advancing vs. 1,332 declining with 182 unchanged. The Drugs industry currently sits up 0.1% versus the S&P 500, which is up 0.3%. On the negative front, top decliners within the industry include Novartis ( NVS), down 1.8%, Eli Lilly and ( LLY), down 1.3%, Pfizer ( PFE), down 0.7% and Gilead ( GILD), down 0.5%. A company within the industry that increased today was AstraZeneca ( AZN), up 3.0%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Regeneron Pharmaceuticals ( REGN) is one of the companies pushing the Drugs industry lower today. As of noon trading, Regeneron Pharmaceuticals is down $7.01 (-2.3%) to $296.07 on light volume. Thus far, 439,341 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $293.58-$306.70 after having opened the day at $305.77 as compared to the previous trading day's close of $303.08. Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $30.5 billion and is part of the health care sector. Shares are up 10.1% year-to-date as of the close of trading on Wednesday. Currently there are 8 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold. TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company's earnings per share. Get the full Regeneron Pharmaceuticals Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.